Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.

ABSTRACT:

Introduction

Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD.

Methods

AD neuropathogenic proteins Aβ_1-42, P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls.

Results

Neuronal exosome levels of Aβ_1-42, P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with ag

SUBMITTER: Hamlett ED 

PROVIDER: S-EPMC5812672 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature